1. Field of the Invention
The invention is related to the measuring devices and measurement of anatomical pathologies.
2. Description of the Related Art
The ability to accurately measure the dimensions of anatomical structures is of vital importance. In many cases, the anatomical geometry defines the treatment. A small object, small hole, or short length of anatomical pathology can go untreated because it has little to no clinical significance. Larger objects, holes, and longer length of anatomical pathology may lead to adverse clinical outcomes.
Additionally, many anatomical pathologies are treated with devices, including implantable devices, that are sized to fit the pathology. Knowledge of the specific size of the pathology aids the selection of an appropriately sized treatment device. Using trial and error techniques to determine the proper size of an implantable treatment device undesirably prolongs the surgical procedure, and fitting and removing improperly sized devices often further traumatizes the already-injured anatomical site.
Existing devices do not easily measure tunnel defects in soft tissue within body structures. Tunnel defects can be found in the heart (e.g., patent foramen ovale (PFO), left atrial appendage, mitral valve prolapse, aortic valve defects). Tunnel defects can be found through out the vascular system (e.g., venous valve deficiency, vascular disease, vulnerable plaque, aneurysms (e.g., neurovascular, abdominal aortic, thoracic aortic, peripheral). Tunnel defects can be found in non vascular systems (e.g., stomach with GERD, prostate, lungs).
A device for measuring the width of a distended defect in tissue is disclosed. The device has a longitudinal axis. The device can have a first elongated member. The first elongated member can be configured to expand away from the longitudinal axis. The device can have a second elongated member. The first elongated member can be opposite with respect to the longitudinal axis to the second elongated member. The second elongated member can be configured to expand away from the longitudinal axis. The device can have a lumen, for example, in a catheter. The device can have a porous cover on the lumen.
A method for sizing a tunnel defect. The method can include inserting a measurement tool into the tunnel defect. The method can include distending the tunnel defect into a distended configuration. The method can include measuring the tunnel defect in the distended configuration. Distending can include radially expanding the measurement tool. Measuring can include bending the first measuring wire around a front lip of the tunnel defect. Measuring can include emitting a contrast fluid in the tunnel defect.
Tissue distension devices can be deployed to tunnel defects in tissue. The tissue distension devices can be used to substantially close tunnel defects to treat, for example, patent foramen ovale (PFO), left atrial appendage, mitral valve prolapse, aortic valve defects. Examples of tissue distension devices include those disclosed in U.S. patent application Ser. Nos. 10/847,909, filed May 19, 2004; 11/184,069, filed Jul. 19, 2005; and 11/323,640, filed Jan. 3, 2006., all of which are incorporated by reference herein in their entireties.
To select a properly fitting tissue distension device, a measuring tool can first be deployed to measure the size of the tunnel defect. The tunnel defect can be measured in a relaxed or distended configuration. The tunnel defect can be distended by the measuring tool before or during measurement.
The catheter can have a catheter porous section. The catheter can be entirely substantially non-porous. The catheter can have a catheter non-porous section. The catheter porous section can partially or completely circumferentially surround the catheter. The catheter porous section can have holes or pores in the catheter outer wall. The pores can have pore diameters from about 1 μm (0.04 mil) to about 1 mm (0.04 in.), more narrowly from about 2 μm (0.08 mil) to about 300 μm (10 mil), for example about 150 μm (6.0 mil).
The first and second measuring wires can each have at least one wire radially constrained section and at least one wire radially unconstrained section. The measuring wires can transition from the wire constrained sections to the wire radially unconstrained sections at the wire proximal sheath ports. The first and second measuring wires between the wire proximal sheath ports and the wire distal anchor can be the radially unconstrained sections. The measuring wires can be distally fixed to the catheter at a wire distal anchor. The wire distal anchor can be a hinged or otherwise rotatable attachment, for example, to allow the measuring wire to rotate away from the longitudinal axis at the wire distal anchor during use.
The measurement tool can have a tip extending from a distal end of the catheter. The tip can be blunt or otherwise atraumatic (e.g., made or coated with a softer material than the catheter, made with a soft substantially biocompatible rubber tip). A guide lumen can extend from the tip. The guide lumen can be configured to slidably receive a guidewire. The guide lumen can exit through a dimple in the tip. The tip need not be dimpled at the exit of the guide lumen.
The first measuring wire can removably and slidably reside in or removably and slidably attach to a recessed or raised first track in the catheter outer wall. The second measuring wire can removably and slidably reside in or removably and slidably attach to a recessed or raised second track in the catheter outer wall.
To transform the measurement tool from the radially contracted configuration to the radially expanded configuration, the first and second measuring wires in the wire radially constrained section can be longitudinally translated, as shown by arrows, in a distal direction. The first and second wires, for example, rotatably fixed at the wire distal anchor and not radially constrained between the wire proximal sheath ports and the wire distal anchor, can translate, as shown by arrows, radially outward from the longitudinal axis.
The wire distal anchor and wire sheaths can be fixedly attached to the catheter. The wire distal anchor and wire sheaths can be slidably attached to the catheter.
The catheter and/or tip can have stop. The stop can be longitudinally fixed with respect to the catheter and/or the tip. The stop can be the tip, for example if the diameter of the tip is larger than the diameter of the wire distal anchor. The stop can be configured to interference fit against the wire distal anchor when the wire distal anchor is distally translated beyond a maximum translation point with respect to the catheter and/or tip.
The measuring wires can be longitudinally translated, as shown by arrows, in the wire radially constrained sections. The first and second measuring wires in the wire radially unconstrained sections can be radially expanded or otherwise translated, as shown by arrows, away from the catheter (e.g., longitudinal axis) into a radially expanded configuration, for example by distally translating the measuring wires in the wire radially constrained sections. The first and second measuring wires in the wire radially unconstrained sections can be radially contracted or otherwise translated toward the catheter (e.g., longitudinal axis) into a radially contracted configuration, for example by proximally translating the measuring wires in the wire radially constrained section.
The wire first hinge point can have a wire first hinge angle. The wire second hinge point can have a wire second hinge angle. In a radially expanded configuration, the wire hinge first and second angles can be from about 10° to about 170°, more narrowly from about 30° to about 150°, yet more narrowly from about 45° to about 135°, for example about 125°.
The measuring wires can each have a unique or paired longitudinal position for their wire proximal sheath ports and wire distal anchors. For example, the first and second measuring wires can exit from wire first proximal sheath ports (not shown on
The measuring wires on each side of the catheter (e.g., the first, third, fifth, seventh, ninth and eleventh measuring wires or the second, fourth, sixth, eighth, tenth and twelfth measuring wires) can pass through the same or different sheaths.
The coupler can be flexible. The coupler can substantially bend, for example, permitting the longitudinal axis of the handle to be a substantially non-zero angle (e.g., from about 0° to about 90°) with respect to the longitudinal axis of the catheter. The coupler can permit substantially resistance free rotation between the longitudinal axis of the catheter and the longitudinal axis of the handle.
The markers can be uniformly and/or non-uniformly distributed along the length of the wire body. The markers can be uniformly and/or non-uniformly distributed along the radius of the wire body. The markers can be separate and discrete from the wire body. The markers can be attached to the wire body. The markers can be incorporated inside the wire body. The marker can have configuration symmetrical about one, two, three, or more axes. The marker can have an omnidirectional configuration. The marker can have a configuration substantially spherical, ovoid, cubic, pyramidal, circular, oval, square, rectangular, triangular, or combinations thereof. The marker's radius can be smaller than or substantially equal to the wire body's radius at the location of the marker.
Any or all elements of the measurement tool and/or other devices or apparatuses described herein can be made from, for example, a single or multiple stainless steel alloys, nickel titanium alloys (e.g., Nitinol), cobalt-chrome alloys (e.g., ELGILOY® from Elgin Specialty Metals, Elgin, Ill.; CONICHROME® from Carpenter Metals Corp., Wyomissing, Pa.), nickel-cobalt alloys (e.g., MP35N® from Magellan Industrial Trading Company, Inc., Westport, Conn.), molybdenum alloys (e.g., molybdenum TZM alloy, for example as disclosed in International Pub. No. WO 03/082363 A2, published Oct. 9, 2003, which is herein incorporated by reference in its entirety), tungsten-rhenium alloys, for example, as disclosed in International Pub. No. WO 03/082363, polymers such as polyethylene teraphathalate (PET), polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, aromatic polyesters, such as liquid crystal polymers (e.g., Vectran, from Kuraray Co., Ltd., Tokyo, Japan), ultra high molecular weight polyethylene (i.e., extended chain, high-modulus or high-performance polyethylene) fiber and/or yarn (e.g., SPECTRA® Fiber and SPECTRA® Guard, from Honeywell International, Inc., Morris Township, N.J., or DYNEEMA® from Royal DSM N.V., Heerlen, the Netherlands), polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE), polyether ketone (PEK), polyether ether ketone (PEEK), poly ether ketone ketone (PEKK) (also poly aryl ether ketone ketone), nylon, polyether-block co-polyamide polymers (e.g., PEBAX® from ATOFINA, Paris, France), aliphatic polyether polyurethanes (e.g., TECOFLEX® from Thermedics Polymer Products, Wilmington, Ma.), polyvinyl chloride (PVC), polyurethane, thermoplastic, fluorinated ethylene propylene (FEP), absorbable or resorbable polymers such as polyglycolic acid (PGA), poly-L-glycolic acid (PLGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), polyethyl acrylate (PEA), polydioxanone (PDS), and pseudo-polyamino tyrosine-based acids, extruded collagen, silicone, zinc, echogenic, radioactive, radiopaque materials, a biomaterial (e.g., cadaver tissue, collagen, allograft, autograft, xenograft, bone cement, morselized bone, osteogenic powder, beads of bone) any of the other materials listed herein or combinations thereof. Examples of radiopaque materials are barium sulfate, zinc oxide, titanium, stainless steel, nickel-titanium alloys, tantalum and gold.
Any or all elements of the measurement tool and/or other devices or apparatuses described herein, can be, have, and/or be completely or partially coated with agents and/or a matrix a matrix for cell ingrowth or used with a fabric, for example a covering (not shown) that acts as a matrix for cell ingrowth. The matrix and/or fabric can be, for example, polyester (e.g., DACRON® from E. I. Du Pont de Nemours and Company, Wilmington, Del.), polypropylene, PTFE, ePTFE, nylon, extruded collagen, silicone or combinations thereof.
The measurement tool and/or elements of the measurement tool and/or other devices or apparatuses described herein and/or the fabric can be filled, coated, layered and/or otherwise made with and/or from cements, fillers, glues, and/or an agent delivery matrix known to one having ordinary skill in the art and/or a therapeutic and/or diagnostic agent. Any of these cements and/or fillers and/or glues can be osteogenic and osteoinductive growth factors.
Examples of such cements and/or fillers includes bone chips, demineralized bone matrix (DBM), calcium sulfate, coralline hydroxyapatite, biocoral, tricalcium phosphate, calcium phosphate, polymethyl methacrylate (PMMA), biodegradable ceramics, bioactive glasses, hyaluronic acid, lactoferrin, bone morphogenic proteins (BMPs) such as recombinant human bone morphogenetic proteins (rhBMPs), other materials described herein, or combinations thereof.
The agents within these matrices can include any agent disclosed herein or combinations thereof, including radioactive materials; radiopaque materials; cytogenic agents; cytotoxic agents; cytostatic agents; thrombogenic agents, for example polyurethane, cellulose acetate polymer mixed with bismuth trioxide, and ethylene vinyl alcohol; lubricious, hydrophilic materials; phosphor cholene; anti-inflammatory agents, for example non-steroidal anti-inflammatories (NSAIDs) such as cyclooxygenase-1 (COX-1) inhibitors (e.g., acetylsalicylic acid, for example ASPIRIN® from Bayer AG, Leverkusen, Germany; ibuprofen, for example ADVIL® from Wyeth, Collegeville, Pa.; indomethacin; mefenamic acid), COX-2 inhibitors (e.g., VIOXX® from Merck & Co., Inc., Whitehouse Station, N.J.; CELEBREX® from Pharmacia Corp., Peapack, N.J.; COX-1 inhibitors); immunosuppressive agents, for example Sirolimus (RAPAMUNE(, from Wyeth, Collegeville, Pa.), or matrix metalloproteinase (MMP) inhibitors (e.g., tetracycline and tetracycline derivatives) that act early within the pathways of an inflammatory response. Examples of other agents are provided in Walton et al, Inhibition of Prostoglandin E2 Synthesis in Abdominal Aortic Aneurysms, Circulation, Jul. 6, 1999, 48-54; Tambiah et al, Provocation of Experimental Aortic Inflammation Mediators and Chlamydia Pneumoniae, Brit. J. Surgery 88 (7), 935-940; Franklin et al, Uptake of Tetracycline by Aortic Aneurysm Wall and Its Effect on Inflammation and Proteolysis, Brit. J. Surgery 86 (6), 771-775; Xu et al, Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium, J. Biological Chemistry 275 (32) 24583-24589; and Pyo et al, Targeted Gene Disruption of Matrix Metalloproteinase-9 (Gelatinase B) Suppresses Development of Experimental Abdominal Aortic Aneurysms, J. Clinical Investigation 105 (11), 1641-1649 which are all incorporated by reference in their entireties.
A drug can be deployed from the catheter porous section, for example, similar to the method of deploying the contrast fluid.
A distension device size can be determined as described, supra. The measurement tool can be radially contracted and removed from the tunnel defect, or the coupler and/or the elements of the measurement tool proximal to the coupler can be detached from the remainder of the measurement tool and removed. If the entire measurement tool is removed from the tunnel defect, a distension device can be selected that has a size that substantially matches (e.g., is equivalent when the distension device is in a substantially or completely radially expanded configuration) the size of the distended tunnel defect. The distension device can be deployed to the tunnel defect, for example along the guidewire. The guidewire can be removed. The distension device can be, for example, a filter, stopper, plug, any distending device described in U.S. patent application Ser. Nos. 10/847,909, filed May 19, 2004; 11/184,069, filed Jul. 19, 2005; and 11/323,640, filed Jan. 3, 2006, all of which are incorporated by reference herein in their entireties, or any combinations thereof.
Any elements described herein as singular can be pluralized (i.e., anything described as “one” can be more than one). Any species element of a genus element can have the characteristics or elements of any other species element of that genus. The above-described configurations, elements or complete assemblies and methods and their elements for carrying out the invention, and variations of aspects of the invention can be combined and modified with each other in any combination.
This application is a continuation of PCT Application No. PCT/U.S. 06/28239 filed Jul. 19, 2006 which claims priority to U.S. Provisional Application No. 60/700,359, filed Jul. 19, 2005, both of which are incorporated herein in its entirety.
Number | Date | Country | |
---|---|---|---|
60700359 | Jul 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2006/028239 | Jul 2006 | US |
Child | 12016965 | US |